|
Characteristic
|
No. of patients
|
Percentage (%)
|
|---|
|
Age (years)
|
|
<50
|
232
|
64.8
|
|
≥50
|
126
|
35.2
|
|
Sex
|
|
Male
|
255
|
71.2
|
|
Female
|
103
|
28.8
|
|
T categorya
|
|
T3
|
64
|
17.9
|
|
T4
|
294
|
82.1
|
|
N categorya
|
|
N0
|
66
|
18.4
|
|
N1
|
113
|
31.6
|
|
N2
|
118
|
33.0
|
|
N3
|
61
|
17.0
|
|
Tumor volume (mL)
|
|
≤46.4
|
219
|
61.2
|
|
>46.4
|
139
|
38.8
|
|
WHO histological type
|
|
I
|
25
|
7.0
|
|
II–III
|
333
|
93.0
|
|
Chemotherapy
|
|
None
|
21
|
5.9
|
|
Concurrent or NACT or adjuvant
|
47
|
13.1
|
|
Concurrent + NACT
|
39
|
10.9
|
|
Concurrent + adjuvant
|
10
|
2.8
|
|
NACT + adjuvant
|
92
|
25.7
|
|
NACT + concurrent + adjuvant
|
149
|
41.6
|
|
Prescribed total dose (Gy)
|
|
<73.92
|
111
|
31.0
|
|
≥73.92
|
247
|
69.0
|
-
WHO World Health Organization, NACT neoadjuvant chemotherapy
-
aThe 7th American Joint Committee on Cancer (AJCC) staging system was used for T and N classification
